¿A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study-Assess Safety/Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine-Administered Concomitantly with Routine Vaccines to Healthy Infants.

StatusActive
Effective start/end date6/01/195/06/23

Funding

  • GlaxoSmithKline: $8,000.00

Keywords

  • Biotechnology & Drug Development, Immunology